WO2018004739A1 - Novel rapid-deposition thin-film forming compositions as effective wound care treatment - Google Patents
Novel rapid-deposition thin-film forming compositions as effective wound care treatment Download PDFInfo
- Publication number
- WO2018004739A1 WO2018004739A1 PCT/US2016/069420 US2016069420W WO2018004739A1 WO 2018004739 A1 WO2018004739 A1 WO 2018004739A1 US 2016069420 W US2016069420 W US 2016069420W WO 2018004739 A1 WO2018004739 A1 WO 2018004739A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thin
- film forming
- film
- forming composition
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 208
- 239000010409 thin film Substances 0.000 title claims abstract description 43
- 238000011282 treatment Methods 0.000 title abstract description 26
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims abstract description 90
- 239000010408 film Substances 0.000 claims abstract description 29
- 239000002904 solvent Substances 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 25
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000002421 anti-septic effect Effects 0.000 claims abstract description 20
- 229960003260 chlorhexidine Drugs 0.000 claims abstract description 20
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960001774 octenidine Drugs 0.000 claims abstract description 11
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 7
- 230000001681 protective effect Effects 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 82
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 71
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 53
- 235000019441 ethanol Nutrition 0.000 claims description 30
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 claims description 29
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 claims description 24
- 229920001220 nitrocellulos Polymers 0.000 claims description 22
- 229940079938 nitrocellulose Drugs 0.000 claims description 22
- 239000000020 Nitrocellulose Substances 0.000 claims description 21
- 239000000853 adhesive Substances 0.000 claims description 17
- 230000001070 adhesive effect Effects 0.000 claims description 17
- -1 poly(methylacrylate- isobutene-monoisopropylmaleate) Polymers 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 claims description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 10
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 8
- 241000723346 Cinnamomum camphora Species 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 8
- 229930008380 camphor Natural products 0.000 claims description 8
- 229960000846 camphor Drugs 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 8
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 8
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 8
- 239000006184 cosolvent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 241001136616 Methone Species 0.000 claims description 6
- 230000000845 anti-microbial effect Effects 0.000 claims description 6
- 239000002826 coolant Substances 0.000 claims description 6
- 229920001651 Cyanoacrylate Polymers 0.000 claims description 5
- 239000000227 bioadhesive Substances 0.000 claims description 5
- 239000003589 local anesthetic agent Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical group CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 claims description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 4
- FAAHNQAYWKTLFD-UHFFFAOYSA-N 1-butan-2-ylpyrrolidin-2-one Chemical compound CCC(C)N1CCCC1=O FAAHNQAYWKTLFD-UHFFFAOYSA-N 0.000 claims description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- 229940041616 menthol Drugs 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 3
- 229940116229 borneol Drugs 0.000 claims description 3
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229960001777 castor oil Drugs 0.000 claims description 2
- 229960004926 chlorobutanol Drugs 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 229940014259 gelatin Drugs 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000010492 gellan gum Nutrition 0.000 claims description 2
- 239000000216 gellan gum Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 229940059904 light mineral oil Drugs 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- ALPGGWRLBYFVIU-UHFFFAOYSA-N methane;propane-1,2,3-triol Chemical compound C.OCC(O)CO ALPGGWRLBYFVIU-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 235000019271 petrolatum Nutrition 0.000 claims description 2
- 229940067107 phenylethyl alcohol Drugs 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 150000003505 terpenes Chemical class 0.000 claims description 2
- 235000007586 terpenes Nutrition 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 235000010487 tragacanth Nutrition 0.000 claims description 2
- 239000000196 tragacanth Substances 0.000 claims description 2
- 229940116362 tragacanth Drugs 0.000 claims description 2
- 229920001664 tyloxapol Polymers 0.000 claims description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004224 tyloxapol Drugs 0.000 claims description 2
- 150000003672 ureas Chemical class 0.000 claims description 2
- 239000003871 white petrolatum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 40
- 208000027418 Wounds and injury Diseases 0.000 abstract description 40
- 208000015181 infectious disease Diseases 0.000 abstract description 16
- 238000002360 preparation method Methods 0.000 abstract description 16
- 239000007788 liquid Substances 0.000 abstract description 12
- 229920000153 Povidone-iodine Polymers 0.000 abstract description 11
- 229960001621 povidone-iodine Drugs 0.000 abstract description 11
- 230000001580 bacterial effect Effects 0.000 abstract description 7
- 239000000645 desinfectant Substances 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 5
- 241000224489 Amoeba Species 0.000 abstract description 4
- 230000002538 fungal effect Effects 0.000 abstract description 4
- 230000003612 virological effect Effects 0.000 abstract description 4
- 208000004210 Pressure Ulcer Diseases 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 3
- 208000000558 Varicose Ulcer Diseases 0.000 abstract description 3
- 231100000397 ulcer Toxicity 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 description 51
- 210000003491 skin Anatomy 0.000 description 42
- 238000012360 testing method Methods 0.000 description 36
- 239000000243 solution Substances 0.000 description 35
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 24
- 239000011630 iodine Substances 0.000 description 24
- 229910052740 iodine Inorganic materials 0.000 description 24
- CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 description 21
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000012046 mixed solvent Substances 0.000 description 15
- 239000000969 carrier Substances 0.000 description 14
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 12
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 12
- 244000005700 microbiome Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 8
- 235000019345 sodium thiosulphate Nutrition 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229940035535 iodophors Drugs 0.000 description 2
- 229940045505 klebsiella pneumoniae Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 241000352262 Potato virus B Species 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010048629 Wound secretion Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 150000004287 bisbiguanides Chemical class 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
- 229950010048 enbucrilate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 239000013047 polymeric layer Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- MDDUHVRJJAFRAU-YZNNVMRBSA-N tert-butyl-[(1r,3s,5z)-3-[tert-butyl(dimethyl)silyl]oxy-5-(2-diphenylphosphorylethylidene)-4-methylidenecyclohexyl]oxy-dimethylsilane Chemical compound C1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)C(=C)\C1=C/CP(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 MDDUHVRJJAFRAU-YZNNVMRBSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 208000012313 wound discharge Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A61F13/01008—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/106—Halogens or compounds thereof, e.g. iodine, chlorite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/206—Biguanides, e.g. chlorohexidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Definitions
- Liquid bandages provide a topical skin treatment for minor cuts and sores. They are mixtures of chemicals which create a polymeric layer binding to the skin, thereby protecting the wound by keeping dirt and germs out while maintaining the moisture in the wound area. See, e.g., R. Petkewich, Chemical & Engineering News, 2008,vol. 86, 24, page 61. Liquid bandage is typically prepared by dissolving a polymer in a carrier solvent (usually water or an alcohol), sometimes with an added antiseptic and local anesthetic which sometimes can be the alcohol itself. These products protect the wound by forming a thin film of polymer when the carrier solvent evaporates.
- a carrier solvent usually water or an alcohol
- polymers suitable for preparing liquid bandages may include but are not limited to polyvinylpyrrolidone (water based), pyroxylin/nitrocellulose or poly(methylacrylate-isobutene-monoisopropylmaleate) (alcohol based), and acrylate or siloxane polymers (hexamethyldisiloxane or isooctane solvent based).
- liquid bandages In addition to their use in replacing conventional bandages for minor cuts and scrapes, liquid bandages have also found use in surgical and veterinary offices, as they cause less trauma and do not have to be removed like sutures (stitches) and staples. Liquid bandages are increasingly finding use with the military, where they can be used to rapidly stanch a wound until proper medical attention can be obtained.
- Povidone iodine is a complex of polyvinylpyrrolidone (povidone or PVP) and iodine. It is also called iodophor and contains 9-12% effective iodine. It is a powerful disinfectant with a broad spectrum of applications and is strongly effective against viruses, bacteria, fungi, and mold spores. It causes little irritation on skin and has low toxicity and lasting effect, and can be used safely and easily. It basically does not cause irritation on tissue and is widely used to disinfect skin and mucous membrane, e.g., for pre-surgical cleaning and disinfection of surgical site and wound.
- Povidone is hydrophilic and can carry iodine to cell membrane. When the PVP-I complex contacts the cell wall, the iodine is released and then complexes with amino acids of bacterial protein to denature it and, at the same time, oxidize the active groups of the bacteria's protoplasmic protein so that the bacteria dies rapidly.
- Povidone iodine is a very good bactericidal agent with no antibiotic resistance. In common use, povidone iodine's concentration is between 0.1% and 10%. Current povidone iodine preparations are in the forms of gel, suppository, cream, solution, with concentration ranging from 1% to 10%.
- Chlorhexidine is an antibacterial used as an antiseptic and for other applications. It is a cationic polybiguanide (bisbiguanide). Chlorhexidine is used in disinfectants (disinfection of the skin and hands), cosmetics (additive to creams, toothpaste, deodorants, and antiperspirants ⁇ , and pharmaceutical products (preservative in eye drops, active substance in wound dressings and antiseptic mouthwashes). See, e.g., Thomas Giithner et a!., "Guanidine and Derivatives", Ullman's Encyclopedia of Industrial Chemistry (7th ed.), Wiley, 2007, p. 13.
- chlorhexidine salts dissociate and release the positively charged chlorhexidine cation.
- the bactericidal effect is a result of the binding of this cationic molecule to negatively charged bacterial cell walls.
- this results in a bacteriostatic effect; at high concentrations, membrane disruption results in cell death.
- Ch!oraPrep * preoperative skin preparation currently on the market is chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v.
- This invention is based on Applicant's surprisingly unexpected discovery that rapid- deposition thin-film compositions of PVP-I, chlorhexidine, or octenidine not only exhibit sustained release properties as such to provide a long acting anti-bacterial effect, but also significantly reduce toxicity and irritation to the wound on skin. As such, the invention provides non-toxic compositions of PVP-I, chlorhexidine, or octenidine for wound healing or skin preparation.
- One aspect of this invention is a rapid-deposition thin-film forming compositions each comprising an antiseptic, a non-aqueous solvent, and a film-forming material dissolved in the non-aqueous solvent, wherein the compositions yield a continuous and flexible protective film upon substantial removal of the solvent.
- composition may be interchanged with the term “formulation.”
- continuous and flexible protective film refers to a film that is does not have many holes or consists of many small pieces, and the film is thin (e.g., less than 1 mm in thickness), and the film does not break when it is slightly or gently bent.
- substantially as in “substantial removal of the solvent” means that the majority (e.g., at least 75%, 85%, 99%, 98%, or 99%) of the solvent is removed, e.g., by evaporation.
- compositions of this invention can be in the form of a solution, cream, gel, or ointment, emulsion, or spray and are useful, e.g., for topical wound treatments (such as an instant bandage).
- topical wound treatments such as an instant bandage.
- a composition of this invention When a composition of this invention is applied to a wound, it form a rapid deposition film on the wound when the solvent is substantially removed from the composition (e.g., by evaporation) and the film seals the wound to prevent the wound from contact germs, bacteria, or other undesired substances. In addition, the film will slowly release the antiseptic and protect the wound.
- the thin-film forming compositions of this invention are non-toxic to skin cells and will promote wound healing. Meanwhile, the rapid- deposition film composition is stable in storage for 1, 3, 6, 12, or even 24 months under light, without noticeable changes in physical properties or chemical composition.
- the rapid deposition thin-film formed on a wound not only protects the wound from infections or contamination, but also
- the antiseptic contained in the compositions of this invention includes povidone iodine (PVP-I), chlorhexidine, octenidine, or a combination thereof.
- PVP-I povidone iodine
- chlorhexidine and octenidine suitable for the present invention include chlorhexidine digluconate and octenidine dihydrochloride, although other chlorhexidine or octenidine may be used as well.
- the antiseptic can be contained in the composition at a concentration between 0.01% and 10%, between 0.1% and 2.5%, between 0.1% and 2.0%, or between 0.5% and 2.0% (weight/weight or weight/volume). Unless otherwise specified herein, the concentration of any substance in the compositions of this invention can always be either weight/weight or weight/volume.
- the rapid-deposition thin-film forming compositions of this invention contain PVP-I at a concentration between 0.01% and 5%, between 0.1% and 2.5%, or between 0.3 and 2% (weight/weight or weight/vol ume).
- the compositions of this invention contain chlorhexidine at a concentration between 0.1% and 2.5% (weight/weight), or octenidine at a concentration between 0.1% and 2.0% (weight/weight).
- PVP-I is the antiseptic contained in the compositions of this invention, it can be released from the film (formed upon substantial removal of the solvent of the compositions) to kill all bacterial, mycobacterial, viral, fungal, or amoeba through an extended or slow release vehicle or mechanism.
- This extended or slow release allows, in one aspect, to maintain a low concentration of PVP-I on the wounds or surrounding areas to eliminate toxicity, and in another aspect, to achieve longer or extended antiseptic effect against infection.
- the inventors unexpectedly found that the extended or slow release of PVP-I from the films formed by the compositions of this invention surprisingly had demonstrated to be non-toxic to fibroblasts.
- the film-forming material contained in the compositions of this invention includes polyvinylbutyral (PVB), a vinylpyrrolidone and vinyl acetate copolymer, polyvinylpyrrolidone, ethyl cellulose, nitrocellulose, poly(methylacrylate- isobutene-monoisopropylmaleate), acrylate polymer, polysiloxane, or a combination thereof.
- PVB polyvinylbutyral
- PVB has proved to be particularly suitable.
- the film-forming material can be contained in the compositions of this invention at a concentration between 1% and 20%, between 1% and 10%, or between 5% and 10% (weight/weight or weight/volume).
- the thin-film forming compositions of this invention include ethanol, propanol, isopropanol, isopentane, ethyl acetate, acetone, or a combination thereof, as the solvent or co-solvent.
- ethanol propanol
- isopropanol isopentane
- ethyl acetate is particularly helpful.
- acetone is particularly helpful.
- the thin-film forming compositions of this invention may still include a cooling agent, a lubricant, an antimicrobial preservative, a co-solvent, a surfactant, a viscosity agent, or a bio-adhesive agent, as excipients.
- cooling agents contained in the compositions of this invention include, but are not limited to camphor, borneol, menthol, methone glycerin acetyl ester, methone glycerin ester, methone glycerin carboxamide, methane glycerol ketal, alkyl- substituted urea, sulfonamide, terpene analog, borneol, furanone, or phosphine oxide, and a combination thereof.
- menthol or camphor is particularly suitable.
- a cooling agent can provide coolness sensation on the skin and mucosal surfaces.
- Lubricants can provide comfort on the wound.
- suitable lubricants contained in the compositions of this invention include, but are not limited to, propylene glycol, glycerin, propylene glycol, blended polyvinyl alcohol, polyvinyl alcohol, polyethylene glycol 400, light mineral oil, castor oil, hydroxypropyl methylcellulose, hypromellose, Carbopol 980, white petrolatum, soy lecithin, sodium carboxyl methylcellulose, hydroxypropyl methylcellulose, hypromellose, and a combination thereof.
- Suitable antimicrobial preservatives contained in the compositions of this invention include, but are not limited to, benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, EDTA, sorbic acid, Onamer M, and a combination thereof.
- the antimicrobial preservative can be contained in the compositions of this invention at a concentration between 0.001% and 1.0% (weight/weight or weight/volume). However, it is preferred that a preservative is not needed for PVP-I compositions since PVP-I is self-preservative.
- co-solvent or surfactant contained in the compositions of this invention include, but are not limited to, polysorbate 20, polysorbate 60, polysorbate 80, a polyoxyethylene surfactant, a polyoxypropylene surfactant (e.g. Pluronic F-68, F-84, and P- 103), cyclodextrin, tyloxapol, and a combination thereof.
- the co-solvent or surfactant can be contained in the composition at a level from 0.01% to 2%, from 0.01% to 1%, from 0.1% to 1%, or from 0.1% to 0.5% (weight/weight or weight/volume), although typically such co- solvents are used at a level of from 0.01% to 2% by weight.
- viscosity builder agent contained in the compositions of this invention include, but are not limited to, polyvinyl alcohol, polyvinylpyrrolidone (PVP), methyl cellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, or hyaluronic acid.
- the viscosity builder agent can be contained in the composition at a level of from 0.01% to 2%, from 0.01% to 1%, from 0.1% to 1%, or from 0.1% to 0.5% (weight/weight or weight/volume), although typically such agents are used at a level of from 0.01% to 2% by weight.
- Bio-adhesive agents can be used in the compositions of this invention to increase the retention time of the drug (antiseptic) gradient over the biological substrates (skin).
- suitable bio-adhesive agent contained in the compositions of this invention include, but are not limited to, PVP, xanthan gum, locust bean gum, acacia gum, hydroxypropyl methylcellulose (HPMC), sodium alginate, pectin, gelatin, carbomer, polyvinylalcohol, gellan gum, tragacanth, acacia, or sodium carboxymethyl cellulose.
- compositions of this invention include PVP-I or chlorhexidine at a concentration of 0.5% to 2.5%, PVB at a concentration of 5% to 10%, ethanol at a concentration of 50% to 60% or isopropanol at a concentration of 50% to 70%, and ethyl acetate at a concentration of 8% to 10%.
- These compositions may optionally further include acetone at a concentration of 20% to 25%, castor oil at a concentration of 0.1% to 1%, or camphor at a concentration of 1% to 2%.
- compositions of this invention further include sugar, potassium lodate, potassium iodide, a local anesthetic, or a topical skin adhesive.
- Sugar can be optionally added to the compositions of this invention to promote wound healing as additional excipients; whereas potassium lodate and/or potassium iodide can be added to improve stability of dilute povidone iodine solution during storage.
- Topical anesthetics can be added to relieve temporary pain on the wound. Examples of suitable topical anesthetics include, but are not limited to, proparacaine, lidocaine, and a combination thereof.
- Topical skin adhesives have gained popularity in wound closure practices.
- the Skin adhesives currently on the market include derivatives of cyanoacrylates such as EpiGlu ® , HistoacryfTopical Skin Adhesive, DERMABOND ADVANCED * Topical Skin Adhesive, SurgiSeaf Adhesive.
- Examples of the topical skin adhesive suitable for the compositions of this invention include cyanoacrylate and a derivative thereof.
- the inventors have unexpectedly discovered the film-forming compositions of this invention can be combined with topical skin adhesives for the treatment and prevention of pre- and/or post-surgical infections with surprisingly good results.
- the antiseptic and topical skin adhesives can exist together as one mixture of the antiseptic and the skin adhesives, or they can exist as two ingredients and be placed in separate compartments in a skit/applicator or two skits/applicators. When they are placed in separate compartments, the two ingredients can be applied together at the same time or sequentially (i.e., one after the other).
- compositions of this invention have proven to be useful for the treatment and prevention of infections in wounds, ulcers (e.g., decubitus ulcers and stasis ulcers), cuts, or burns, or against infections from bacterial, mycobacterial, viral, fungal, or amoeba causes, as well as treatment to prevent such infections in appropriate clinical settings, e.g., as liquid bandages or dressings. Additionally, the compositions of this invention are also useful for the treatment of infections; as a disinfectant skin preparation for pre- and/or post-surgical operations.
- Fig. 1 shows a transdermal diffusion apparatus (Franz single-room diffusion cell) used to investigate the drug release properties of compositions of this invention.
- Fig. 2 shows iodine release profiles from PVP-l-containing thin film-forming compositions of this invention, as reflected by the amounts of available iodine.
- Fig. 3 shows pictures to show skin treatment effects of different agents (including two compositions of this invention) on mice.
- PVP-I is a polymer complex soluble in water.
- the first step was to screen the solvent phase, as shown in Table 1:
- Example 2 Pre-formulations with nitrocellulose as film-forming material
- a mixed solvent was prepared with 4.5 g ethanol and 3.3 g ethyl acetate. 3.9 g of the just prepared ethanol/ethyl acetate mixed solvent was then mixed with 0.2 g PVP-I and the mixture was stirred until PVP-I fully dissolved, resulting in a clear violet solution without insoluble substance. This PVP-I solution was set aside. 1.0 g nitrocellulose was added to the remaining ethanol/ethyl acetate mixed solvent and the mixture was stirred until nitrocellulose fully dissolved and the mixture transformed into a transparent viscous gel without insoluble substance remaining. The gel and the PVP-I solution were then mixed and stirred vigorously until the mixture became cloudy. After being left at the room temperature for one week, the PVP-I formulation was observed to have separated layers.
- a mixed solvent was prepared with 1.5 g ethanol and 6.0 g ethyl acetate. 3.75 g of the ethanol/ethyl acetate mixed solvent just prepared was mixed with 0.2 g PVP-I and the mixture was stirred until PVP-I was fully dissolve, resulting in a clear violet solution without insoluble substance. This PVP-I solution was set aside. 1.0 g nitrocellulose was added to the remaining ethanol/ethyl acetate mixed solvent and stirred until it was fully dissolved and the mixture transformed into a transparent viscous gel without insoluble substance remaining. The gel and the PVP-I solution were then mixed and stirred vigorously until the mixture became cloudy. After being left at the room temperature for one week, the PVP-I formulation was observed with layer separation.
- liquid bandage formulations with transparent appearance of this example could not be achieved through adjusting the preparation process when nitrocellulose was used as film-forming material.
- the film should be impermeable to water.
- hydrophobic film-forming materials were selected to make film-forming formulations of this invention.
- PVB Polyvinylbutyral
- % refers to the percentage of total formulation volume (W/W).
- Example 9 Evaluation of stability of film-forming PVP-I composition after stored at 37 °C for 3 months.
- Example 10 Additional examples of thin-film forming PVP-I compositions
- PVP-I compositions were prepared to include the following ingredients: povidone Iodine (0.5% to 2.5%), polyvinylbutylral (5% to 10%), ethanol (50% to 60%), ethyl acetate (8% to 10%), acetone (20% to 25%) (optional), castor oil (0.1% to 1%), and camphor (1% to 2%) (optional).
- a PVP-I Film-Forming composition of this invention was applied on human skin, and the film-forming process was observed.
- the solvent completely evaporated from the composition and resulted in a thin film on the skin within 2 minutes.
- the film was continuous and adhesive, and it stuck to the skin and was hard to be scraped off under water rinse.
- Example 13 Film-forming compositions containing 2% chlorhexidine digluconate (CHG)
- Film-forming liquid bandage formulations of this invention containing 2% CHG were prepared according to formulations set forth below in Table 11.
- Example 14 Film-forming composition containing 0.5% chlorhexidine digluconate
- a film-forming liquid bandage composition containing 0.5% chlorhexidine digluconate (CHG) was prepared according to formulation set forth below in Table 12. The CHG composition was applied to the skin and quickly formed a film under 30 seconds. Table 12.
- Example 15 A film-forming composition containing 0.5% octenidine dihydrochloride
- a film-forming liquid bandage composition containing 0.5% octenidine dihydrochloride (by weight) was prepared according to formulation set forth below in Table 13.
- the octenidine dihydrochloride film -forming composition was applied to the skin and quickly formed a thin film under 30 seconds.
- a transdermal diffusion apparatus (Franz single-room diffusion cell) shown in Fig. 1 was used to investigate the drug release properties of PVP-I film-forming compositions of this invention, and PVP-I film-forming composition's sustained release function was assessed by measuring the rate of drug diffusion through a semi-permeable membrane with non- barrier properties and reach the receiving media according to the following procedure.
- a dialysis membrane (soaked with purified water) of a suitable size was then placed between the receiving cell (Down Cell) and supply cell.
- a magnetic stirrer was put in the receiving cell.
- Purified water was used as release medium, and the temperature was set at 32 °C.
- Purified water was added as release medium from the sampling port, and brought into contact with a dialysis membrane.
- the diffusion cell was placed in a 32 °C water bath, and a magnetic stirrer was turned on. At time intervals 5 minutes, 30 minutes, 60 minutes, 120 minutes, 4 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours, all the liquid in the receiving cell was removed, and the samples were supplemented with an equal amount purified water at the same temperature.
- the concentration of available iodine was measured as described below to calculate the cumulative drug release amount.
- l d is the content of iodine in 10 g liquid bandage composition sample at different test times
- AV is the volume of sodium thiosulfate solution consumed
- Ws is the weight of the sample. 6 samples of each composition were used to obtain the average amount of available iodine.
- the release profiles of iodine from PVP-I film-forming composition (liquid bandage), as reflected by the amounts of available iodine, are shown in Fig. 2. As shown in Fig. 2, approximately 92.89 ⁇ 2.14% of iodine was released from the solution samples within half an hour.
- Example 17 Film-forming compositions in vivo efficacy experiments
- PVP-I film-forming composition CHG film-forming composition
- SurgiSeal ® skin adhesive SurgiSeal ® skin adhesive
- NewSkin ® liquid Bandages were used as four treatment groups to treat the wound infections, continuous treatment for eight days, respectively.
- the wound healing was observed, the wound lengths were measured, and the wounds were photographed.
- Fig. 3, including all the sub-figures, include the pictures showing the wounds at different stages of the healing.
- mice group which received PVP-I film-forming composition and CHG film- forming composition treatment wound was healed fully in the next day, and no inflammation was observed and no tissue fluid linking out.
- PVP-I film-forming composition and CHG film-forming composition unexpectedly provided much better results for the wound healing.
- NCTC clone 929 (L cell, L-929, derivative of Strain L) was purchased from TongpaiBio (Shanghai, China). The cells were incubated in Dulbecco minimum essential medium (DMEM) with 10%FBS in an incubator at 37 ⁇ 2 °C under an atmosphere of 5% C0 2 for 24 hours before extracts addition. The medium was supplemented with 100 U/mL penicillin and 100 mg/mL streptomycin.
- DMEM Dulbecco minimum essential medium
- L929 cells at a density of 1x104 cell/well were seeded and incubated in 96-well ( ⁇ /well) plates for 24 hours at 37 °C under an atmosphere of 5% C0 2 . Then cells were incubated with different extracts (extracts of PVP-I film, extracts of film-forming composition without PVP-I, ⁇ /well), and blank DMEM were used as control. After incubation for 24 hours, 150 ⁇ culture medium was sucked away and 50 ⁇ of Cell Titer-Glo ® (Promega) was added for assay the luminescence cell viability using PHERAstar FS (BMG LABTECH).
- Cell viability(%) QE>S x 100% wherein OD s is the luminescence value of samples and OD CO ntroi is the luminescence value of blank DMEM.
- test substances the speed of the microbicidal activity was measured using a select battery of microorganisms including antibiotic resistant organisms. The contact time was selected at
- Staphylococcus aureus (MRSA) ATCC#33592 were selected as test microorganism(s) by the microbiology lab-Microchem Laboratory in Texas, USA.
- test microorganism was prepared, usually by growth in liquid culture medium.
- the test culture may be supplemented with an artificial soil load, such as horse or fetal bovine serum, for one-step cleaner/sanitizer claims.
- Sterilized carriers were inoculated with a volume of the test culture. Inoculated slides were dried in an incubator. Only completely dried carriers were used in the test.
- Test carriers were treated with the test substance and incubated for the predetermined contact time.
- Control carriers were treated with a buffered saline solution and were allowed to sit for the predetermined contact time.
- test and control carriers were chemically neutralized. Dilutions of the neutralized test substance were evaluated using appropriate growth media to determine the surviving microorganisms at the respective contact time.
- ASTM International defines passing criteria to be a 3 LoglO or 99.9% reduction in the treated test carriers when compared to the control carriers. Testing Parameters used in the Study
- Test Carrier Size 1 inch x 2 inch Replicates: Triple
- Carrier Dry Temp 25°C ⁇ 2°C
- Carrier Dry Time ⁇ 15 minutes
- Test carriers for this testing were ⁇ l"x2" surfaces of rehydrated VITRO-SKIN.
- VITRO- SKIN was rehydrated as per Sponsor's instructions ⁇ 18 hours prior to conducting testing. Study Notes
- PBS Phosphate Buffered Saline
- Test carriers were spot inoculated with 0.020 mL test inoculum due to the VITRO- SKIN sticking and tearing when a spreader was used.
- A Number of viable test microorganisms on the test carriers after the contact time
- Example 20 Combination of antiseptics and cyanoacrylates as film-forming compositions.
- the Povidone Iodine film-forming composition was mixed with butyl cyanoacrylate, a clear solution was obtained and the set time of the film was reduced within 30 seconds.
- the film-forming composition can be employed as a solution, cream, a gel, or an ointment, an emulsion, or a spray on the wound to form a rapid-deposition thin-film on the skin.
- compositions are useful for the treatment and prevention of infections in wounds, ulcers, cuts and burns; for the treatment of infections in decubitus ulcers and stasis ulcers.
- the compositions are suitable as a treatment against infections from bacterial, mycobacterial, viral, fungal, or amoeba causes, as well as treatment to prevent such infections in appropriate clinical settings.
- compositions are useful as skin preparations before and /or after surgical operations as disinfectants.
Abstract
The present invention provides thin-film forming compositions comprising an antiseptic (e.g., povidone iodine, chlorhexidine, or octenidine), a non-aqueous solvent, and a film-forming material dissolved in the non-aqueous solvent, wherein the composition yields a continuous and flexible protective film upon substantial removal of the solvent. The compositions are useful for the treatment and prevention of infections in wounds, ulcers (e.g., decubitus ulcers and stasis ulcers), cuts, or burns, or against infections from bacterial, mycobacterial, viral, fungal, or amoeba causes, as well as for prevention of such infections in appropriate clinical settings (e.g., as liquid bandages or dressings). Additionally, the compositions of this invention are also useful for the treatment of infections and as a disinfectant skin preparation for pre- and/or post-surgical operations.
Description
NOVEL RAPID-DEPOSITION THIN-FILM FORMING COMPOSITIONS AS
EFFECTIVE WOUND CARE TREATMENT
Reference to Related Application
[01] The present application claims priority to US Application No. 62/355,911 filed on June 29, 2016, the contents of which are incorporated herein by reference in their entireties.
Background of the Invention
[02] Liquid bandages provide a topical skin treatment for minor cuts and sores. They are mixtures of chemicals which create a polymeric layer binding to the skin, thereby protecting the wound by keeping dirt and germs out while maintaining the moisture in the wound area. See, e.g., R. Petkewich, Chemical & Engineering News, 2008,vol. 86, 24, page 61. Liquid bandage is typically prepared by dissolving a polymer in a carrier solvent (usually water or an alcohol), sometimes with an added antiseptic and local anesthetic which sometimes can be the alcohol itself. These products protect the wound by forming a thin film of polymer when the carrier solvent evaporates. Examples of polymers suitable for preparing liquid bandages may include but are not limited to polyvinylpyrrolidone (water based), pyroxylin/nitrocellulose or poly(methylacrylate-isobutene-monoisopropylmaleate) (alcohol based), and acrylate or siloxane polymers (hexamethyldisiloxane or isooctane solvent based).
[03] In addition to their use in replacing conventional bandages for minor cuts and scrapes, liquid bandages have also found use in surgical and veterinary offices, as they cause less trauma and do not have to be removed like sutures (stitches) and staples. Liquid bandages are increasingly finding use with the military, where they can be used to rapidly stanch a wound until proper medical attention can be obtained.
[04] Existing traditional wound dressings still suffers poor waterproof, good permeability and fast curing speed. They are not conducive to the wound secretions and discharge, thus easy to allow bacterial growth and reproduction, causing or aggravating infections, especially when compared to susceptible anaerobic bacteria such as tetanus. Liquid dressings formulated with water usually take a long time to dry and, once in contact with water, would get damaged easily. It is preferable to use a solvent phase with better tolerability towards water, soap and rubbing effect to make the dressings. Therefore it's desired to develop a
fast curing waterproof liquid bandage composition containing an antiseptic for wound treatment to prevent skin infection.
[05] The most common skin preparation agents used today include products containing iodophors or chlorhexidine. However, the toxicity of higher concentrations of iodophors or chlorhexidine cannot be underestimated.
[06] Povidone iodine (PVP-I) is a complex of polyvinylpyrrolidone (povidone or PVP) and iodine. It is also called iodophor and contains 9-12% effective iodine. It is a powerful disinfectant with a broad spectrum of applications and is strongly effective against viruses, bacteria, fungi, and mold spores. It causes little irritation on skin and has low toxicity and lasting effect, and can be used safely and easily. It basically does not cause irritation on tissue and is widely used to disinfect skin and mucous membrane, e.g., for pre-surgical cleaning and disinfection of surgical site and wound. The principle of sterilization is mainly through the release of hydrated iodine which has bactericidal effect. Povidone is hydrophilic and can carry iodine to cell membrane. When the PVP-I complex contacts the cell wall, the iodine is released and then complexes with amino acids of bacterial protein to denature it and, at the same time, oxidize the active groups of the bacteria's protoplasmic protein so that the bacteria dies rapidly. Povidone iodine is a very good bactericidal agent with no antibiotic resistance. In common use, povidone iodine's concentration is between 0.1% and 10%. Current povidone iodine preparations are in the forms of gel, suppository, cream, solution, with concentration ranging from 1% to 10%.
[07] Chlorhexidine is an antibacterial used as an antiseptic and for other applications. It is a cationic polybiguanide (bisbiguanide). Chlorhexidine is used in disinfectants (disinfection of the skin and hands), cosmetics (additive to creams, toothpaste, deodorants, and antiperspirants}, and pharmaceutical products (preservative in eye drops, active substance in wound dressings and antiseptic mouthwashes). See, e.g., Thomas Giithner et a!., "Guanidine and Derivatives", Ullman's Encyclopedia of Industrial Chemistry (7th ed.), Wiley, 2007, p. 13. At physiologic pH, chlorhexidine salts dissociate and release the positively charged chlorhexidine cation. The bactericidal effect is a result of the binding of this cationic molecule to negatively charged bacterial cell walls. At low concentrations of chlorhexidine, this results in a bacteriostatic effect; at high concentrations, membrane disruption results in cell death. See, e.g., Jerrold B. Leikin et a!., eds. "Chlorhexidine Gluconate", Poisoning and Toxicology Handbook (4th ed.), informa, 2008, pp. 183-184. The
Ch!oraPrep* preoperative skin preparation currently on the market is chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v.
[08] Since 1987, octenidine has been used in Europe as an antiseptic at a concentration of 0.1-2.0%. It is cheaper to prepare than chlorhexidine and has been a substitute for chlorhexidine, with respect to its slow action and concerns about the carcinogenic impurity 4-chloroaniline. No resistance had been observed as of 2007. See, e.g., Z. Al-Doori et al., J Antimicrob Chemother, 2007; 59: 1280-1.
[09] Although povidone iodine commonly used at full strength as widely used and highly effective antiseptics, this concentration appears to be toxic to the cells involved in wound healing. See e.g., A.K. Ba!in el a!,, "Dilute povidone-iodine solutions inhibit human skin fibroblast growth," Dermoto! Surg., March 2002, 28(3): 210-4. The article reported the studies of dilute PVP-I solutions on inhibition of human skin fibroblast growth and that fibroblast growth was progressively retarded at 0.01% and 0.025%, and totally inhibited by 0.1% and 1% PVP-I solutions. Partial recovery of cell growth after limited exposure of cultures to dilute solutions of PVP-I was noted. This study shows that even dilute PVP-I solutions are toxic to human fibroblasts.
[010] This invention is based on Applicant's surprisingly unexpected discovery that rapid- deposition thin-film compositions of PVP-I, chlorhexidine, or octenidine not only exhibit sustained release properties as such to provide a long acting anti-bacterial effect, but also significantly reduce toxicity and irritation to the wound on skin. As such, the invention provides non-toxic compositions of PVP-I, chlorhexidine, or octenidine for wound healing or skin preparation.
Summary of the Invention
[011] One aspect of this invention is a rapid-deposition thin-film forming compositions each comprising an antiseptic, a non-aqueous solvent, and a film-forming material dissolved in the non-aqueous solvent, wherein the compositions yield a continuous and flexible protective film upon substantial removal of the solvent.
[012] As used herein, the term "composition" may be interchanged with the term "formulation."
[013] As used herein, the term "continuous and flexible protective film" refers to a film that is does not have many holes or consists of many small pieces, and the film is thin (e.g., less than 1 mm in thickness), and the film does not break when it is slightly or gently bent.
[014] As used herein, the term substantial as in "substantial removal of the solvent" means that the majority (e.g., at least 75%, 85%, 99%, 98%, or 99%) of the solvent is removed, e.g., by evaporation.
[015] The compositions of this invention can be in the form of a solution, cream, gel, or ointment, emulsion, or spray and are useful, e.g., for topical wound treatments (such as an instant bandage). When a composition of this invention is applied to a wound, it form a rapid deposition film on the wound when the solvent is substantially removed from the composition (e.g., by evaporation) and the film seals the wound to prevent the wound from contact germs, bacteria, or other undesired substances. In addition, the film will slowly release the antiseptic and protect the wound. The thin-film forming compositions of this invention are non-toxic to skin cells and will promote wound healing. Meanwhile, the rapid- deposition film composition is stable in storage for 1, 3, 6, 12, or even 24 months under light, without noticeable changes in physical properties or chemical composition. The rapid deposition thin-film formed on a wound not only protects the wound from infections or contamination, but also is waterproof.
[016] In some embodiments, the antiseptic contained in the compositions of this invention includes povidone iodine (PVP-I), chlorhexidine, octenidine, or a combination thereof. Examples of chlorhexidine and octenidine suitable for the present invention include chlorhexidine digluconate and octenidine dihydrochloride, although other chlorhexidine or octenidine may be used as well.
[017] The antiseptic can be contained in the composition at a concentration between 0.01% and 10%, between 0.1% and 2.5%, between 0.1% and 2.0%, or between 0.5% and 2.0% (weight/weight or weight/volume). Unless otherwise specified herein, the concentration of any substance in the compositions of this invention can always be either weight/weight or weight/volume.
[018] In some specific embodiments, the rapid-deposition thin-film forming compositions of this invention contain PVP-I at a concentration between 0.01% and 5%, between 0.1% and 2.5%, or between 0.3 and 2% (weight/weight or weight/vol ume). Alternatively, the compositions of this invention contain chlorhexidine at a concentration between 0.1% and
2.5% (weight/weight), or octenidine at a concentration between 0.1% and 2.0% (weight/weight).
[019] When PVP-I is the antiseptic contained in the compositions of this invention, it can be released from the film (formed upon substantial removal of the solvent of the compositions) to kill all bacterial, mycobacterial, viral, fungal, or amoeba through an extended or slow release vehicle or mechanism. This extended or slow release allows, in one aspect, to maintain a low concentration of PVP-I on the wounds or surrounding areas to eliminate toxicity, and in another aspect, to achieve longer or extended antiseptic effect against infection. The inventors unexpectedly found that the extended or slow release of PVP-I from the films formed by the compositions of this invention surprisingly had demonstrated to be non-toxic to fibroblasts.
[020] In some embodiments, the film-forming material contained in the compositions of this invention includes polyvinylbutyral (PVB), a vinylpyrrolidone and vinyl acetate copolymer, polyvinylpyrrolidone, ethyl cellulose, nitrocellulose, poly(methylacrylate- isobutene-monoisopropylmaleate), acrylate polymer, polysiloxane, or a combination thereof. Among these materials, PVB has proved to be particularly suitable.
[021] The film-forming material can be contained in the compositions of this invention at a concentration between 1% and 20%, between 1% and 10%, or between 5% and 10% (weight/weight or weight/volume).
[022] In some other embodiments, the thin-film forming compositions of this invention include ethanol, propanol, isopropanol, isopentane, ethyl acetate, acetone, or a combination thereof, as the solvent or co-solvent. Among these additional compounds, ethyl acetate, acetone, or a combination thereof is particularly helpful.
[023] The thin-film forming compositions of this invention may still include a cooling agent, a lubricant, an antimicrobial preservative, a co-solvent, a surfactant, a viscosity agent, or a bio-adhesive agent, as excipients.
[024] Examples of suitable cooling agents contained in the compositions of this invention include, but are not limited to camphor, borneol, menthol, methone glycerin acetyl ester, methone glycerin ester, methone glycerin carboxamide, methane glycerol ketal, alkyl- substituted urea, sulfonamide, terpene analog, borneol, furanone, or phosphine oxide, and a combination thereof. Among these examples, menthol or camphor is particularly suitable. A cooling agent can provide coolness sensation on the skin and mucosal surfaces.
[025] Lubricants can provide comfort on the wound. Examples of suitable lubricants contained in the compositions of this invention include, but are not limited to, propylene glycol, glycerin, propylene glycol, blended polyvinyl alcohol, polyvinyl alcohol, polyethylene glycol 400, light mineral oil, castor oil, hydroxypropyl methylcellulose, hypromellose, Carbopol 980, white petrolatum, soy lecithin, sodium carboxyl methylcellulose, hydroxypropyl methylcellulose, hypromellose, and a combination thereof.
[026] Examples of suitable antimicrobial preservatives contained in the compositions of this invention include, but are not limited to, benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, EDTA, sorbic acid, Onamer M, and a combination thereof. The antimicrobial preservative can be contained in the compositions of this invention at a concentration between 0.001% and 1.0% (weight/weight or weight/volume). However, it is preferred that a preservative is not needed for PVP-I compositions since PVP-I is self-preservative.
[027] Examples of co-solvent or surfactant contained in the compositions of this invention include, but are not limited to, polysorbate 20, polysorbate 60, polysorbate 80, a polyoxyethylene surfactant, a polyoxypropylene surfactant (e.g. Pluronic F-68, F-84, and P- 103), cyclodextrin, tyloxapol, and a combination thereof. The co-solvent or surfactant can be contained in the composition at a level from 0.01% to 2%, from 0.01% to 1%, from 0.1% to 1%, or from 0.1% to 0.5% (weight/weight or weight/volume), although typically such co- solvents are used at a level of from 0.01% to 2% by weight.
[028] Examples of viscosity builder agent contained in the compositions of this invention include, but are not limited to, polyvinyl alcohol, polyvinylpyrrolidone (PVP), methyl cellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, or hyaluronic acid. The viscosity builder agent can be contained in the composition at a level of from 0.01% to 2%, from 0.01% to 1%, from 0.1% to 1%, or from 0.1% to 0.5% (weight/weight or weight/volume), although typically such agents are used at a level of from 0.01% to 2% by weight.
[029] Bio-adhesive agents can be used in the compositions of this invention to increase the retention time of the drug (antiseptic) gradient over the biological substrates (skin). Examples of suitable bio-adhesive agent contained in the compositions of this invention include, but are not limited to, PVP, xanthan gum, locust bean gum, acacia gum,
hydroxypropyl methylcellulose (HPMC), sodium alginate, pectin, gelatin, carbomer, polyvinylalcohol, gellan gum, tragacanth, acacia, or sodium carboxymethyl cellulose.
[030] In still some other embodiments, the compositions of this invention include PVP-I or chlorhexidine at a concentration of 0.5% to 2.5%, PVB at a concentration of 5% to 10%, ethanol at a concentration of 50% to 60% or isopropanol at a concentration of 50% to 70%, and ethyl acetate at a concentration of 8% to 10%. These compositions may optionally further include acetone at a concentration of 20% to 25%, castor oil at a concentration of 0.1% to 1%, or camphor at a concentration of 1% to 2%.
[031] In yet still some other embodiments, the compositions of this invention further include sugar, potassium lodate, potassium iodide, a local anesthetic, or a topical skin adhesive.
[032] Sugar can be optionally added to the compositions of this invention to promote wound healing as additional excipients; whereas potassium lodate and/or potassium iodide can be added to improve stability of dilute povidone iodine solution during storage. Topical anesthetics can be added to relieve temporary pain on the wound. Examples of suitable topical anesthetics include, but are not limited to, proparacaine, lidocaine, and a combination thereof.
[033] Topical skin adhesives have gained popularity in wound closure practices. The Skin adhesives currently on the market include derivatives of cyanoacrylates such as EpiGlu®, HistoacryfTopical Skin Adhesive, DERMABOND ADVANCED* Topical Skin Adhesive, SurgiSeaf Adhesive. Examples of the topical skin adhesive suitable for the compositions of this invention include cyanoacrylate and a derivative thereof. The inventors have unexpectedly discovered the film-forming compositions of this invention can be combined with topical skin adhesives for the treatment and prevention of pre- and/or post-surgical infections with surprisingly good results.
[034] As ingredients of the thin-film forming compositions of this invention, the antiseptic and topical skin adhesives (e.g., cyanoacrylates) can exist together as one mixture of the antiseptic and the skin adhesives, or they can exist as two ingredients and be placed in separate compartments in a skit/applicator or two skits/applicators. When they are placed in separate compartments, the two ingredients can be applied together at the same time or sequentially (i.e., one after the other).
[035] The thin-film forming compositions of this invention have proven to be useful for the treatment and prevention of infections in wounds, ulcers (e.g., decubitus ulcers and stasis ulcers), cuts, or burns, or against infections from bacterial, mycobacterial, viral, fungal, or amoeba causes, as well as treatment to prevent such infections in appropriate clinical settings, e.g., as liquid bandages or dressings. Additionally, the compositions of this invention are also useful for the treatment of infections; as a disinfectant skin preparation for pre- and/or post-surgical operations.
Brief Descriptions of the Drawings
[036] Fig. 1 shows a transdermal diffusion apparatus (Franz single-room diffusion cell) used to investigate the drug release properties of compositions of this invention.
[037] Fig. 2 shows iodine release profiles from PVP-l-containing thin film-forming compositions of this invention, as reflected by the amounts of available iodine.
[038] Fig. 3 (including Figs. 3A1-3E4) shows pictures to show skin treatment effects of different agents (including two compositions of this invention) on mice.
Detailed Description of the Invention
Example 1: Screening of solvent
[039] PVP-I is a polymer complex soluble in water. To prepare a non-aqueous phase liquid dressing, the first step was to screen the solvent phase, as shown in Table 1:
Table 1. Solubility of Povidone Iodine (PVP-I) in Different Organic Solvents
NOTE: %: the percentage of total formulation volume (W/W)
[040] To make PVP-I liquid ba ndage solutions to form rapid-deposition film on skin surface, low boiling-point volatile solvents were selected to study solubility of PVP-I and the time required for the solvent to evaporate to dryness. Table 1 above shows that PVP-I was readily soluble in ethanol and insoluble in ethyl acetate, acetone, isopentane and n-pentane. The use of a mixed solvent could significantly improve PVP-l's solubility. When ethanol alone was the solvent, the drying time was 3 minutes 27 seconds. A mixed solvent has even shorter drying time. Pa rticularly, when the mixed solvent contains acetone and isopentane (which have low boiling points), drying time had been shortened to less than 2 minutes, as the mixed solvents could form azeotropes, which was easier to evaporate. Isopentane had some irritation to skin, and thus its dosage could not be too high. From the study, dosage greater than 15% of isopentane could not shorten the drying time, but instead increase the skin irritation. n-Pentane is not used because of its pungent smell. Therefore, after a preliminary study, ethanol, ethyl acetate, acetone and isopentane alone or combinations were chosen as the solvent phase in this invention.
Example 2. Pre-formulations with nitrocellulose as film-forming material
[041] After screening of the non-aqueous solvents, preparations of PVP-I liquid bandage pre-formulations with nitrocellulose as film-forming material were carried out as nitrocellulose has been widely used in liquid bandage products such as New Skin products. The formulation samples were left at room temperature, and their stability data were shown in Table 2:
Table 2. Pre-formulations with nitrocellulose as film-forming material
[042] The results in Table 2 showed that the mixture of PVP-I and nitrocellulose was not inductive for preparing a clear liquid bandage formulation. Even after adjusting the amount of nitrocellulose, PVP-I, ethanol, or the mixture of ethyl acetate and acetone, the appearances of prepared samples were turbid and insoluble substance was observed. Layer separation was observed with all samples after they were left at the room temperature for 1 week, possibly due to the water solubility of PVP-I and hydrophobicity of nitrocellulose nitrate. After mixing, the mixture still could not be completely dissolved in the solvent, resulting in precipitations.
Example 3. Adjustment of formulation preparation processes:
[043] Based on the initial screening of formulations as described in Example 2, we found that using the mixture of PVP-I and nitrocellulose to prepare a liquid bandage resulted in cloudy appearance of the prepared samples, and separation of layers was observed after samples were left at the room temperature for one week. These indicated that samples were unstable. To determine if different formulation processes could result in clear liquid bandage formulations. Shown in Table 3 below are the formulations prepared by different preparation processes:
Table 3. Additional Liquid Bandage Formulations
Preparation Process:
Formulation 19
[044] 2.5 g ethanol and 0.2 g PVP-I were mixed and stirred to dissolve until a clear violet solution was obtained with no insoluble substance observed. This clear solution was set aside. Separately, 2.0 g ethanol, 3.3 g ethyl acetate, and 1.0 g nitrocellulose were mixed and stirred to dissolve until the mixture became a transparent viscous gel with no insoluble substance observed. The PVP-l-ethanol solution and the nitrocellulose gel just prepared were mixed and stirred vigorously to give rise a cloudy mixture (i.e., a PVP-I formulation).
After the PVP-I formulation was left at the room temperature for one week, layer separation was observed.
Formulation 20
[045] A mixed solvent was prepared with 4.5 g ethanol and 3.3 g ethyl acetate. 3.9 g of the just prepared ethanol/ethyl acetate mixed solvent was then mixed with 0.2 g PVP-I and the mixture was stirred until PVP-I fully dissolved, resulting in a clear violet solution without insoluble substance. This PVP-I solution was set aside. 1.0 g nitrocellulose was added to the remaining ethanol/ethyl acetate mixed solvent and the mixture was stirred until nitrocellulose fully dissolved and the mixture transformed into a transparent viscous gel without insoluble substance remaining. The gel and the PVP-I solution were then mixed and stirred vigorously until the mixture became cloudy. After being left at the room temperature for one week, the PVP-I formulation was observed to have separated layers.
Formulation 22
[046] A mixed solvent was prepared with 1.5 g ethanol and 6.0 g ethyl acetate. 3.75 g of the ethanol/ethyl acetate mixed solvent just prepared was mixed with 0.2 g PVP-I and the mixture was stirred until PVP-I was fully dissolve, resulting in a clear violet solution without insoluble substance. This PVP-I solution was set aside. 1.0 g nitrocellulose was added to the remaining ethanol/ethyl acetate mixed solvent and stirred until it was fully dissolved and the mixture transformed into a transparent viscous gel without insoluble substance remaining. The gel and the PVP-I solution were then mixed and stirred vigorously until the mixture became cloudy. After being left at the room temperature for one week, the PVP-I formulation was observed with layer separation.
[047] The liquid bandage formulations with transparent appearance of this example could not be achieved through adjusting the preparation process when nitrocellulose was used as film-forming material. Precipitation formed from the mixture of PVP-I and nitrocellulose, was not a simple problem of solubility, but the compatibility of the two substances.
Example 4. Screening of film-forming materials
[048] After a film is formed the wound with the film-forming formulations of this invention, the film should be impermeable to water. As such, hydrophobic film-forming materials were selected to make film-forming formulations of this invention. After a preliminary screening of examples of the formulation of this invention and optimization of the preparation processes, samples with qualified appearance were not obtained by using nitrocellulose.
The film-forming materials were selected again, and the results are shown below in Table 4:
Table 4. Screening of the film-forming materials
NOTE: %: the percentage of total formulation volume (W/W)
[049] Adjustments of the proportion of ethanol, ethyl acetate, acetone and isopentane, and change the dosage of nitrocellulose, could not improve the transparency of the product. Then, ethyl cellulose was investigated as a film-forming material, and appearance of product was cloudy, too. Polyvinylbutyral (PVB) was investigated as a film-forming material, and it unexpectedly resulted in a clear and burgundy solution. Despite different appearances of the formulations with different film-forming materials, the liquid compositions prepared with three different film-forming materials, upon application on the skin, quickly became a continuous, flexible film, and were easy to apply. Nitrocellulose, polyvinylbutyral, and ethyl cellulose were preferable film-forming materials, wherein the most preferable film-forming material was PVB.
Example 5. Screening of Mixed Solvent (I)
[050] With ethanol, ethyl acetate, acetone and isopentane as solvents and PVB as the film- forming material, further studies of the ratio of the mixed solvent were carried out. Film formation time was measured, and formulation stability was investigated at 25 °C. The results were shown below in Table 5.
Table 5
NOTE: %: the percentage of total formulation volume (W/W)
[051] As shown in Table 5, formulations using only ethanol and iso-pentane (Formulation 26 and 35), or formulations using only ethanol and ethyl acetate (Formulation 33), the film- forming time was significantly slower than the formulation using the mixture of three solvents. After being placed at 25 °C for 22 days, the viscosity of the formulations in this example, except Formulation 32, increased considerably, which resulted in each formulation forming a block with no mobility. The change of the percentage of isopentane had no effect on film-forming time. Due to its irritation to the skin and low boiling point, isopentane was ruled out as excipient of the formulations. Therefore, the preferable solvents for the formulations of this invention include the mixture of ethanol, ethyl acetate and/or acetone. Example 6. Screening of Mixed Solvent (II)
[052] Studies of screening of Mixed Solvent (I) showed that adding acetone into formulations could prevent increase of viscosity and agglomeration after the formulations were placed for a period of time. Further studies of the ratio of the mixed solvent were carried out. Film formation time was measured, and stability was investigated at 40 °C for 5 days and 10 days. The results are shown below in Table 6:
Table 6
NOTE: %: the percentage of total formulation volume (W/W)
[053] As shown in Table 6, lowering the amount of polyvinylbutyral could not solve the problem of agglomeration after the sample was placed for a period of time. Secondly, adding acetone could greatly alleviate the problem of increasing viscosity. The film-forming time of Formulation 47 was shortest, however the film was thinner. Moreover, reducing the amount of castor oil could shorten the film-forming time. Therefore, the preferable percentages of various ingredients are: PVB around 6% -8%; solvent being the mixture of ethanol and ethyl acetate and acetone (which contained 50-60% of ethanol, about 10% ethyl acetate, about 20-30% acetone); castor oil around 0.5%, and camphor around 1% -2%.
Example 7. Screening of polyvinylbutyral
[054] Polyvinylbutyral (PVB) polymers with different molecular weights (MWs) were evaluated. Formulations of this invention prepared with PVBs of different MWs were placed in the dark or under light at 60 °C for 10 days. Film drying time, appearance, viscosity and
available iodine content were measured as criteria to determine stability of the sample formulations. Mechanical properties of the formulations were measured as well. The results are shown below in Table 7:
Table 7
NOTE: % refers to the percentage of total formulation volume (W/W).
[055] When choosing polyvinylbutyral (PVB) of a lower molecular weight (90,000-120,000) instead of higher molecular weight (170,000-250,000) as film-forming material, a clear and
stable solution was unexpectedly obtained even without acetone as a solvent, and rapid thin-film formation was also unexpectedly achieved within 90 seconds.
Example 8. Determination of availa ble iodine amount
Titrate with 0.01044 mol/L sodium thiosulfate solution:
[056] Configuration of titration solution : 5mL pipettes were used to pipet 5mL 0.1044 mol/L sodium thiosulfate solution (calibrated) to a 50 mL volumetric flask, and purified water was then added to the flask to give a 0.01044 mol/L sodium thiosulfate solution.
Preparation of samples:
[057] A sample of 5 g was taken and ethanol was added to the sa mple to reach the volume of 50 mL, shake well to give a sample for titration.
[058] Shown below in Table 8 are the available iodine amounts obtained from the Formulations that had been placed at 60 °C for 10 days are shown below in Table 8.
Table 8
Example 9. Evaluation of stability of film-forming PVP-I composition after stored at 37 °C for 3 months.
[059] The following three PVP-I liquid bandage compositions of this invention were used in evaluation of their stability after they were stored at 37 °C for 3 months: (1) Sample 1: PVB 8%, MW: 90,000-120,000, PVP-I 2%; (2) Sample 2: PVB 8%, MW: 90,000-120,000W, PVP-I 1%; and (3) Sample 3 :PVB 8%, MW:9-12W, PVP-I 0.5%)
[060] The concentration of available iodine, viscosity and set time (time to dry when applying the liquid bandage on skin) were measured and recorded in Tablet 9. Test samples were made and tested in triplets.
Table 9. The Stability of PVP-I Film-forming Compositions stored at 37 °C for 3 months
2 month at 37°C
Available Iodine Viscosity (CP) set time (seconds) Id (mg)
Samplesl-1 19.08 120.1 76
Samplesl-2 20.42 97.9 89
Samplesl-3 18.61 112..9 85
Average 19.37 109.0 83
Samples2-1 10.54 130.7 96
Samples2-2 9.98 125.7 103
Samples2-3 10.69 106.8 97
Average 10.4 121.1 99
Samples3-1 3.19 97.8 105
Samples3-2 2.76 103.7 89
Samples3-3 3.47 114.9 98
Average 3.14 105.5 97
3 month at 37°C
Available Iodine Viscosity (CP) Set time (seconds) Id (mg)
Samplesl-1 19.47 125.9 108
Samplesl-2 18.06 108.9 115
Samplesl-3 21.43 119.6 96
Average 19.65 118.1 106
Samples2-1 10.13 105.7 86
Samples2-2 10.17 129.5 100
Samples2-3 10.27 110.5 94
Average 10.19 115.2 93
Samples3-1 2.89 97.0 93
Samples3-2 3.23 103.6 81
Samples3-3 3.80 120.9 94
Average 3.31 107.2 89
Table 10. Comparison of Stability of different concentration of PVP-I Film-Forming Compositions after being stored at 37 °C for 3 months (assuming 0 day data as 100%)
[061] The concentrations of available iodine content reduced from 20.70 mg to 19.65 mg, a 5.1% reduction after Sample 1 (PVB 8%, MW:9-12W, PVP-I 2% ) had been stored at 37 °C for 3 months, and sample2 (PVB 8%, MW:9-12W, PVP-I 1% ) had a 17.8% reduction (12.4 mg to 10.19 mg), sample3 (PVB 8%, MW:9-12W, PVP-I 0.5% ) had a 36.7% reduction in three test groups, which indicated that the 2% povidone iodine containing sample was preferable choice. The viscosity and set time of the three samples did not change significantly.
Example 10. Additional examples of thin-film forming PVP-I compositions
[062] Additional examples of thin-film forming PVP-I compositions were prepared to include the following ingredients: povidone Iodine (0.5% to 2.5%), polyvinylbutylral (5% to 10%), ethanol (50% to 60%), ethyl acetate (8% to 10%), acetone (20% to 25%) (optional),
castor oil (0.1% to 1%), and camphor (1% to 2%) (optional).
Example 11. PVP-I Film-Forming Spray Preparation :
[063] 0.8 g of PVB of a molecular weight 90,000-120,000, 6.75 g of ethyl alcohol absolute, 2.2 g of ethyl acetate, 0.05 g of castor oil, 0.2 g of PVP-I, and a suitable amount of difluormethane were mixed together and vigorously stirred until PVP-I was dissolved. The solution was filled into spray apparatus as PVP-I Film-Forming Spray.
Example 12. Demonstration of Film-Forming Process:
[064] A PVP-I Film-Forming composition of this invention was applied on human skin, and the film-forming process was observed. The solvent completely evaporated from the composition and resulted in a thin film on the skin within 2 minutes. The film was continuous and adhesive, and it stuck to the skin and was hard to be scraped off under water rinse.
Example 13. Film-forming compositions containing 2% chlorhexidine digluconate (CHG)
[065] Film-forming liquid bandage formulations of this invention containing 2% CHG were prepared according to formulations set forth below in Table 11.
Table 11. Film-Forming Chlorhexidine Compositions
Example 14. Film-forming composition containing 0.5% chlorhexidine digluconate
[066] A film-forming liquid bandage composition containing 0.5% chlorhexidine digluconate (CHG) was prepared according to formulation set forth below in Table 12. The CHG composition was applied to the skin and quickly formed a film under 30 seconds.
Table 12.
Example 15. A film-forming composition containing 0.5% octenidine dihydrochloride
[067] A film-forming liquid bandage composition containing 0.5% octenidine dihydrochloride (by weight) was prepared according to formulation set forth below in Table 13. The octenidine dihydrochloride film -forming composition was applied to the skin and quickly formed a thin film under 30 seconds.
Table 13.
Example 16. In vitro release test of PVP-I Film-forming composition
[068] A transdermal diffusion apparatus (Franz single-room diffusion cell) shown in Fig. 1 was used to investigate the drug release properties of PVP-I film-forming compositions of this invention, and PVP-I film-forming composition's sustained release function was assessed by measuring the rate of drug diffusion through a semi-permeable membrane with non- barrier properties and reach the receiving media according to the following procedure.
[069] First, 50 g PVP-I film-forming composition (liquid Bandage) was added to the supply cell (Up Cell), and the solvent was allowed to evaporate to form thin films. A PVP-I solution of the same PVP-I concentration was used as a positive control, and in accordance to the available iodine 0.1 g sample configuration, to fill in the supply cell.
[070] A dialysis membrane (soaked with purified water) of a suitable size was then placed between the receiving cell (Down Cell) and supply cell. A magnetic stirrer was put in the receiving cell. Purified water was used as release medium, and the temperature was set at 32 °C. Purified water was added as release medium from the sampling port, and brought into contact with a dialysis membrane. The diffusion cell was placed in a 32 °C water bath, and a magnetic stirrer was turned on. At time intervals 5 minutes, 30 minutes, 60 minutes,
120 minutes, 4 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours, all the liquid in the receiving cell was removed, and the samples were supplemented with an equal amount purified water at the same temperature. The concentration of available iodine was measured as described below to calculate the cumulative drug release amount.
Measurement of Concentration of Available Iodine
[071] 5 mL of a sodium thiosulfate standard solution (0.1044mol/L) was pipetted to a 50 mL volumetric flask, and then deionized water was added to the sodium thiosulfate solution to the total volume of 50 mL.
[072] 5 g of a test sample was added into a 100 mL beaker and ethanol was added to the beaker for the total weight of 50 g, and the mixture was stirred and mixed well. The sample was titrated to colorless by the sodium thiosulfate solution just prepared, and the volume of the sodium thiosulfate solution consumed was recorded. The volume amount was used for calculating then iodine content based on the following equation:
ld = AVx0.01044xl2.69xlO/(0.1xWs)
wherein, ld is the content of iodine in 10 g liquid bandage composition sample at different test times, AV is the volume of sodium thiosulfate solution consumed, and Ws is the weight of the sample. 6 samples of each composition were used to obtain the average amount of available iodine. The release profiles of iodine from PVP-I film-forming composition (liquid bandage), as reflected by the amounts of available iodine, are shown in Fig. 2. As shown in Fig. 2, approximately 92.89±2.14% of iodine was released from the solution samples within half an hour. By comparison, the release of iodine were 73.83±6.72% from the film-forming composition samples (n=6) after 48 hours, which indicated that the film-forming PVP-I compositions of this invention provided sustain release of iodine. In fact, it was surprisingly and unexpectedly discovered that film-forming PVP-I compositions of this invention had achieved a much slower release of iodine comparing to the same concentration of PVP-I solution.
Example 17. Film-forming compositions in vivo efficacy experiments
[073] To evaluate in vivo efficacy of film-forming compositions of this invention against bacteria on the wound, ICR mice were used animal model. Man-made wounds were infected with bacteria. Four treatment groups with PVP-I film-forming compositions, SurgiSeal® skin adhesive, NewSkin® liquid bandage, and CHG film-forming composition, were studied. Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa bacteria, 5 *
107CFU / ml, 1: 1: 1 were mixed to make bacteria solution.
Animals
[074] 18-20 g ICR mice were randomly divided into four groups of 10. Artificially scraped off hair on the abdomen and back, to show bare skin. A knife was used to draw 2-3cm length wound, with depth to the dermis (bleeding so far). All wounds were infected with mixed bacterial, and set aside.
Study Procedure:
[075] PVP-I film-forming composition, CHG film-forming composition, SurgiSeal® skin adhesive, and NewSkin® liquid Bandages were used as four treatment groups to treat the wound infections, continuous treatment for eight days, respectively. At 0 Day, 2 Day, 4 Day, 6 Day, 8 Day after the beginning of the treatments, the wound healing was observed, the wound lengths were measured, and the wounds were photographed. Fig. 3, including all the sub-figures, include the pictures showing the wounds at different stages of the healing.
Assessment of efficacy
[076] Evaluate wound healing effect using a scoring system and Table 14 is a score shoot from the test.
Table 14
n=10
Observations:
[077] For the mice group which received NewSkin® spraying liquid bandage treatment, the wound was not closed in the next day, and tissue fluid leaked out (2 Days, circle). On day 4, wound was healed, tissue has grown normally, and no infla mmation was observed and no tissue fluid leaked out.
[078] For the mice group which received Surgiseal® skin adhesive treatment, tissue fluid
leaking was observed in the next day (2 D, circle and arrow), and remaining mice's wounds healed normally, no tissue fluid leaked out.
[079] For the mice group which received PVP-I film-forming composition and CHG film- forming composition treatment, wound was healed fully in the next day, and no inflammation was observed and no tissue fluid linking out.
[080] Based on clinical observations after the treatment, the wounds of the four groups of mice received treatment all have been healed. During the early wound healing period, the mice groups received PVP-I film-forming composition and CHG film-forming composition treatment, wounds were healed faster. The mice groups received NewSkin® spraying liquid bandage and Surgiseal® skin adhesive appeared tissue fluid exudation, respectively. PVP-I film-forming composition and CHG film-forming composition unexpectedly provided much better results for the wound healing.
Example 18. PVP-I film-forming composition in vitro safety studies
[081] Following the protocol described in ISO 10993-5:2009 "Biological evaluation of medical devices - Part 5: In vitro cytotoxicity tests", safety of PVP-I film-forming composition was tested in vitro.
Cell line and culture
[082] NCTC clone 929 (L cell, L-929, derivative of Strain L) was purchased from TongpaiBio (Shanghai, China). The cells were incubated in Dulbecco minimum essential medium (DMEM) with 10%FBS in an incubator at 37±2 °C under an atmosphere of 5% C02 for 24 hours before extracts addition. The medium was supplemented with 100 U/mL penicillin and 100 mg/mL streptomycin.
Procedure
[083] Extract preparation: Take PVP-I film-forming composition 0.5g and let solvent evaporate to form films. Then a 2 χ 3cm film was made and incubated at 37 °C for 24 hours within 2 mL DMEM (area/medium = 6 cm2/mL). And extracts from film-forming composition without PVP-I were also made as above-mentioned procedure. Blank DMEM and blank extracts are used as control groups. All the extraction was filtered with a 0.22 μιη membrane before adding into cell.
[084] L929 cells at a density of 1x104 cell/well were seeded and incubated in 96-well (ΙΟΟμΙ/well) plates for 24 hours at 37 °C under an atmosphere of 5% C02. Then cells were incubated with different extracts (extracts of PVP-I film, extracts of film-forming composition
without PVP-I, ΙΟΟμΙ/well), and blank DMEM were used as control. After incubation for 24 hours, 150 μί culture medium was sucked away and 50 μί of Cell Titer-Glo® (Promega) was added for assay the luminescence cell viability using PHERAstar FS (BMG LABTECH).
[085] Assay was repeated two times (n=18/time) to get the average reading, the cell viability calculated according to the following formula:
Cell viability(%) = QE>S x 100% wherein ODs is the luminescence value of samples and ODCOntroi is the luminescence value of blank DMEM.
3) Safety Assessment Criteria:
[086] 24 hours survival rate of more than 70% is regarded as safe. The safety profile of povidone iodine film-forming compositions was assessed and the result is shown in Table 15.
Table 15.
Cell viability (%) 104.9% 97.5% 97.1% 97.7%
[087] The safety/toxicity of PVP-I film-forming compositions passed the safety requirements.
Example 19. Anti-bacterial Efficacy of PVP-I Film-Forming Composition
[088] Surface Time Kill study where bacteria (1 xl08 CFU) were placed on top of dried films
(test substances), the speed of the microbicidal activity was measured using a select battery of microorganisms including antibiotic resistant organisms. The contact time was selected at
1, 15, and 60 minutes, respectively. The following microorganisms Escherichia coli ATCC#
8739, Klebsiellapneumoniae ATCC# 4352, Staphylococcus epidermidis ATCC# 12228, and
Staphylococcus aureus (MRSA) ATCC#33592 were selected as test microorganism(s) by the microbiology lab-Microchem Laboratory in Texas, USA.
Test Method: ASTM International Method E1153, Surface Time Kill
Summary of the Procedure
[089] The test microorganism was prepared, usually by growth in liquid culture medium. The test culture may be supplemented with an artificial soil load, such as horse or fetal bovine serum, for one-step cleaner/sanitizer claims.
[090] Sterilized carriers were inoculated with a volume of the test culture. Inoculated slides were dried in an incubator. Only completely dried carriers were used in the test.
[091] Test carriers were treated with the test substance and incubated for the predetermined contact time.
[092] Control carriers were treated with a buffered saline solution and were allowed to sit for the predetermined contact time.
[093] At the conclusion of the contact time, test and control carriers were chemically neutralized. Dilutions of the neutralized test substance were evaluated using appropriate growth media to determine the surviving microorganisms at the respective contact time.
[094] The effect of the test substance was compared to the effect of the control substance in order to determine microbial reductions.
Passing Criteria
[095] ASTM International defines passing criteria to be a 3 LoglO or 99.9% reduction in the treated test carriers when compared to the control carriers.
Testing Parameters used in the Study
Test Carrier Size: 1 inch x 2 inch Replicates: Triple
Test Substance Volume: 3.0 mL
Culture Growth Media: Tryptic Soy Broth Culture Growth Time: 18-24 hours
Culture Supplement: None Carrier Inoculum Volume: 0.020 ml
Inoculum Concentration: 1 x 108 CFU/ml Carrier Inoculum Area: 1 inch x 2 inch
Carrier Dry Temp: 25°C ± 2°C Carrier Dry Time: <15 minutes
Contact Temp.: Ambient (25°C ± 2°C) Contact Humidity: Ambient
Contact Time: 1 min, 15 min, 1 hr Neutralizer: D/E Neutralizing Broth
Enumeration Plate36°C ± 1°C Enumeration Plate24-48 hours
Incubation Temperature: Incubation Time:
Incubation Conditions: Aerobic
Study Modifications
[096] Test carriers for this testing were ~l"x2" surfaces of rehydrated VITRO-SKIN. VITRO- SKIN was rehydrated as per Sponsor's instructions ~18 hours prior to conducting testing. Study Notes
[097] To evaluate the viability of the test microorganism following the 1-hour contact time, 3.0 mL Phosphate Buffered Saline (PBS) was applied to inoculated test surfaces as a control.
[098] Test carriers were spot inoculated with 0.020 mL test inoculum due to the VITRO- SKIN sticking and tearing when a spreader was used.
Control Results
Neutralization Method: Validated Media Sterility: Sterile
Growth Confirmation: Confirmed, Morphology on TSA
Calculations
■ B-A -
Percent Reduction -! 1 X 100
B wherein:
B = Number of viable test microorganisms on the control carriers after the contact time A = Number of viable test microorganisms on the test carriers after the contact time
,- B -
Log, Q Reduction— Log !— ) wherein:
B = Number of viable test microorganisms on the control carriers after the contact time A = Number of viable test microorganisms on the test carriers after the contact time
Results of the Study
Table 16: Results for E. coli 8739
Test S bstar
The limit of detection for this assay was 5 CFU. Non-detects are represented as zero in the graph above.
Table 17: Results for K. pneumoniae 4352
The limit of detection for this assay was 5 CFU. Non-detects are represented as zero in the graph above.
Table 18: Results for S. epidermidis 12228
The limit of detection for this assay was 5 CFU. Non-detects are represented as zero in the graph above.
Table 19: Results for S. aureus 33592
Tssi Su stan
[099] The limit of detection for this assay was 5 CFU. Non-detects were represented as zero in the graph above.
Conclusion:
[0100] More than 5 LoglO or 99.999% microbial reduction in the treated test carrier (PVP-I film-forming composition) against all three selected microorganisms Escherichia coli ATCC# 8739, Klebsiellapneumoniae ATCC# 4352, Staphylococcus epidermidis ATCC# 12228, and Staphylococcus aureus (M SA) ATCC#33592 when compared to the control carriers.
Example 20. Combination of antiseptics and cyanoacrylates as film-forming compositions.
[0101] The Povidone Iodine film-forming composition was mixed with butyl cyanoacrylate, a clear solution was obtained and the set time of the film was reduced within 30 seconds.
[0102] In another embodiment, the film-forming composition can be employed as a solution, cream, a gel, or an ointment, an emulsion, or a spray on the wound to form a rapid-deposition thin-film on the skin.
[0103] The compositions are useful for the treatment and prevention of infections in wounds, ulcers, cuts and burns; for the treatment of infections in decubitus ulcers and stasis ulcers. The compositions are suitable as a treatment against infections from bacterial, mycobacterial, viral, fungal, or amoeba causes, as well as treatment to prevent such infections in appropriate clinical settings.
[0104] The compositions are useful as skin preparations before and /or after surgical operations as disinfectants.
[0105] The invention has been described herein by reference to certain preferred embodiments. However, as obvious variations thereof will become apparent to those skilled in the art, the invention is not to be considered as limited thereto. All patents, patent applications, and references cited anywhere is hereby incorporated by reference in their entirety.
Claims
1. A thin-film forming composition comprising an antiseptic, a non-aqueous solvent, and a film-forming material dissolved in the non-aqueous solvent, wherein the composition yields a continuous and flexible protective film upon substantial removal of the solvent.
2. The thin-film forming composition of claim 1, wherein the antiseptic comprises povidone iodine (PVP-I), chlorhexidine, or octenidine.
3. The thin-film forming composition of claim 1 or 2, wherein the antiseptic is contained in the composition at a concentration between 0.01% and 10%, between 0.1% and 2.5%, between 0.1% and 2.0%, or between 0.5% and 2.0% (weight/weight or weight/volume).
4. The thin-film forming composition of any of claims 1 to 3, wherein chlorhexidine is
chlorhexidine digluconate, or octenidine is octenidine dihydrochloride.
5. The thin-film forming composition of any of claims 1 to 4, wherein the film-forming
material comprises polyvinylbutyral (PVB), a vinylpyrrolidone and vinyl acetate copolymer, polyvinylpyrrolidone, ethyl cellulose, nitrocellulose, poly(methylacrylate- isobutene-monoisopropylmaleate), acrylate polymer, or polysiloxane.
6. The thin-film forming composition of any of claims 1 to 5, wherein the film-forming material comprises polyvinylbutyral (PVB).
7. The thin-film forming composition of any of claims 1 to 6, wherein the film-forming material is contained in the composition at a concentration between 1% and 20%, or between 5% and 10% (weight/weight or weight/volume).
8. The thin-film forming composition of any of claims 1 to 7, further comprising ethanol, propanol, isopropanol, isopentane, ethyl acetate, acetone, or a combination thereof.
9. The thin-film forming composition of any of claims 1-8, further comprising a cooling agent, a lubricant, an antimicrobial preservative, a co-solvent, a surfactant, a viscosity agent, or a bioadhesive agent.
10. The thin-film forming composition of claim 9, wherein the cooling agent comprises camphor, borneol, menthol, methone glycerin acetyl ester, methone glycerin ester, methone glycerin carboxamide, methane glycerol ketal, alkyl-substituted urea, sulfonamide, terpene analog, furanone, or phosphine oxide.
11. The thin-film forming composition of claim 9, wherein the cooling agent comprises menthol or camphor.
12. The thin-film forming composition of claim 9, wherein the lubricant comprises propylene glycol, glycerin, propylene glycol, blended polyvinyl alcohol, polyvinyl alcohol, polyethylene glycol 400, light mineral oil, castor oil, hydroxypropyl methylcellulose, hypromellose, Carbopol 980, white petrolatum, soy lecithin, sodium carboxyl methylcellulose, hydroxypropyl methylcellulose, hypromellose, or a combination thereof.
13. The thin-film forming composition of claim 9, wherein the antimicrobial preservative comprises benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, EDTA, sorbic acid, Onamer M, or a combination thereof.
14. The thin-film forming composition of claim 9 or 13, wherein the antimicrobial preservative is contained in the composition at a concentration between 0.001% and 1.0% (weight/weight or weight/volume).
15. The thin-film forming composition of claim 9, wherein the co-solvent or surfactant comprises polysorbate 20, polysorbate 60, polysorbate 80, a polyoxyethylene surfactant, a polyoxypropylene surfactant, cyclodextrin, tyloxapol, or a combination thereof.
16. The thin-film forming composition of claim 9 or 15, wherein the co-solvent or surfactant is contained in the composition at a level from 0.01% to 2% (weight/weight or weight/volume).
17. The thin-film forming composition of claim 9, wherein the viscosity builder agent
comprises polyvinyl alcohol, polyvinylpyrrolidone (PVP), methyl cellulose,
hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, or hyaluronic acid.
18. The thin-film forming composition of claim 9 or 17, wherein the viscosity builder agent is contained in the composition at a level of from 0.01% to 2% (weight/weight or weight/volume).
19. The thin-film forming composition of claim 9, wherein the bio-adhesive agent comprises PVP, xanthan gum, locust bean gum, acacia gum, hydroxypropyl methylcellulose (HPMC), sodium alginate, pectin, gelatin, carbomer, polyvinylalcohol, gellan gum, tragacanth, acacia, or sodium carboxymethyl cellulose.
20. The thin-film forming composition of any of claims 2 to 19, wherein the composition comprises PVP-I or chlorhexidine or octenidine at a concentration of 0.5% to 2.5%, PVB at a concentration of 5% to 10%, ethanol at a concentration of 50% to 60% or
isopropanol at a concentration of 50% to 70%, and/or ethyl acetate at a concentration of 8% to 10%.
21. The thin-film forming composition of claim 20, further comprising acetone at a concentration of 20% to 25%, or castor oil at a concentration of 0.1% to 1%, or camphor at a concentration of 1% to 2%.
22. The thin-film forming composition of any of claims 1 to 21, further comprising sugar, or potassium lodate, or potassium iodide, or a local anesthetic, or a topical skin adhesive, or a combination thereof.
23. The thin-film forming composition of claim 22, wherein the topical skin adhesive comprises cyanoacrylate or a derivative thereof.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16907675.9A EP3478234A4 (en) | 2016-06-29 | 2016-12-30 | Novel rapid-deposition thin-film forming compositions as effective wound care treatment |
JP2018568750A JP7054212B2 (en) | 2016-06-29 | 2016-12-30 | A novel fast-adhesive thin-film forming composition as an effective wound care procedure |
CN201680059582.8A CN108135745B (en) | 2016-06-29 | 2016-12-30 | Efficient novel fast deposition film-forming compositions for wound treatment |
HK18108164.3A HK1248511A1 (en) | 2016-06-29 | 2018-06-26 | Novel rapid-deposition thin-film forming compositions as effective wound care treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662355911P | 2016-06-29 | 2016-06-29 | |
US62/355,911 | 2016-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018004739A1 true WO2018004739A1 (en) | 2018-01-04 |
Family
ID=60786284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/069420 WO2018004739A1 (en) | 2016-06-29 | 2016-12-30 | Novel rapid-deposition thin-film forming compositions as effective wound care treatment |
Country Status (6)
Country | Link |
---|---|
US (1) | US11471481B2 (en) |
EP (1) | EP3478234A4 (en) |
JP (1) | JP7054212B2 (en) |
CN (1) | CN108135745B (en) |
HK (1) | HK1248511A1 (en) |
WO (1) | WO2018004739A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110639055A (en) * | 2019-11-07 | 2020-01-03 | 广州市福托康生物科技有限公司 | Wound care ointment and preparation method thereof |
CN110755673A (en) * | 2019-11-07 | 2020-02-07 | 广州市福托康生物科技有限公司 | Sodium carboxymethylcellulose liquid dressing and preparation method thereof |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3817782A1 (en) * | 2018-07-04 | 2021-05-12 | Coloplast A/S | Fibrous wound dressing comprising an antiseptic |
CN108685886B (en) * | 2018-07-18 | 2020-10-13 | 武汉市贝斯特新材料有限责任公司 | Antibacterial film-forming polymer liquid and preparation method thereof |
CN109106976B (en) * | 2018-07-30 | 2021-06-29 | 绍兴百立盛新材料科技有限公司 | Preparation method of liquid band-aid |
CN108939145A (en) * | 2018-08-13 | 2018-12-07 | 西安中天生物医药有限公司 | A kind of liquid adhesive bandage and preparation method thereof |
CN108992462B (en) * | 2018-09-21 | 2022-10-25 | 四川悦康源通药业有限公司 | Compound povidone iodine composition and preparation method thereof |
CN109289084A (en) * | 2018-10-30 | 2019-02-01 | 河南汇博医疗股份有限公司 | A kind of surface of a wound antibacterial liquid dressing and preparation method thereof |
CN109464696A (en) * | 2018-12-05 | 2019-03-15 | 福建易元生物医药有限公司 | A kind of atomizing liquid adhesive bandage |
CN109602727A (en) * | 2018-12-05 | 2019-04-12 | 福建易元生物医药有限公司 | A kind of painting type liquid adhesive bandage |
CN110201218A (en) * | 2018-12-23 | 2019-09-06 | 山东泰开制药有限公司 | Liquid adhesive bandage and preparation method thereof |
CN110201220A (en) * | 2019-05-29 | 2019-09-06 | 利安隆博华(天津)医药化学有限公司 | A kind of liquid adhesive bandage and preparation method thereof improving osmotic absorption rate |
CN112076342A (en) * | 2019-06-12 | 2020-12-15 | 陕西佰傲再生医学有限公司 | Skin wound protection composition and preparation method thereof |
CN110101900A (en) * | 2019-06-20 | 2019-08-09 | 江西高大生物医疗科技有限公司 | A kind of film forming agent of the insulation blocking surface of a wound |
CN110559474A (en) * | 2019-09-09 | 2019-12-13 | 苏州汇涵医用科技发展有限公司 | Liquid wound dressing, method for the production thereof and use thereof |
CN110787164A (en) * | 2019-10-08 | 2020-02-14 | 天津国际生物医药联合研究院 | Application of octenidine in inhibiting acetyl transferase and resisting mycobacterial infection |
CN110882413A (en) * | 2019-12-11 | 2020-03-17 | 河南承东生物科技有限公司 | Water-soluble long-acting physical antibacterial liquid dressing and preparation method thereof |
CN111184906B (en) * | 2020-02-19 | 2020-12-29 | 江南大学 | PVA-based liquid dressing and preparation method thereof |
CN111450310A (en) * | 2020-03-03 | 2020-07-28 | 劳龙斯(上海)医药科技有限公司 | Novel liquid wound dressing and preparation method thereof |
CN111346257B (en) * | 2020-03-12 | 2021-03-23 | 上海市东方医院(同济大学附属东方医院) | A wet dressing for protecting skin and its preparation method |
CN111265498A (en) * | 2020-04-22 | 2020-06-12 | 河南省康星药业股份有限公司 | Film-forming povidone iodine solution and preparation method and application thereof |
CN111744054B (en) * | 2020-07-20 | 2021-05-25 | 哈尔滨乾佰纳生物药业有限公司 | Antibacterial wound surface dressing capable of promoting healing and preparation method thereof |
EP4217013A2 (en) * | 2020-09-23 | 2023-08-02 | Lavipharm S.A. | Liquid bandage system |
CN112245652A (en) * | 2020-10-16 | 2021-01-22 | 合肥贝壳派创新科技有限公司 | Bacteriostatic liquid band-aid capable of quickly forming film and preparation method thereof |
CN112546290A (en) * | 2020-12-17 | 2021-03-26 | 江苏耐雀生物工程技术有限公司 | Antibacterial and anti-inflammatory liquid adhesive bandage and preparation method thereof |
WO2022126629A1 (en) * | 2020-12-18 | 2022-06-23 | 江苏奇力康皮肤药业有限公司 | Liquid adhesive bandage and preparation method therefor |
WO2022133629A1 (en) * | 2020-12-21 | 2022-06-30 | 江苏奇力康皮肤药业有限公司 | Spray type liquid bandage and preparation method therefor |
CN113117136A (en) * | 2021-03-04 | 2021-07-16 | 江西肤宝生物科技有限公司 | Production process and device of traditional Chinese medicine liquid medical dressing |
CN113318122B (en) * | 2021-03-24 | 2022-06-24 | 厦门大开生物科技有限公司 | Disinfectant composition containing povidone iodine and application thereof |
CN115177782B (en) * | 2021-04-02 | 2023-07-18 | 诺一迈尔(山东)医学科技有限公司 | Liquid band-aid with high air permeability and healing promotion function and preparation method thereof |
EP4333804A1 (en) * | 2021-05-07 | 2024-03-13 | Laboratorios Inibsa, S.A. | In-situ film-forming composition |
CN113181420B (en) * | 2021-05-07 | 2022-03-11 | 多能干细胞再生医学科技(广州)有限公司 | Liquid wound dressing for quickly repairing skin superficial injury and preparation method thereof |
CN113456616A (en) * | 2021-07-09 | 2021-10-01 | 潮州市亿生健医药保健品有限公司 | Polyhexamethylene guanidine-based film coating agent for disinfection and preparation method thereof |
CN113679879B (en) * | 2021-08-20 | 2022-09-09 | 广东粤港澳大湾区黄埔材料研究院 | Liquid skin and preparation method and application thereof |
CN114028607A (en) * | 2021-11-26 | 2022-02-11 | 青岛鸿蒙草本医疗科技有限公司 | Liquid dressing and preparation method thereof |
CN114272261A (en) * | 2021-12-29 | 2022-04-05 | 艾威药业(珠海)有限公司 | A topical skin preparation containing povidone iodine for treating psoriasis |
CN114470311A (en) * | 2021-12-31 | 2022-05-13 | 泰州市榕兴医疗用品股份有限公司 | Liquid band-aid and preparation method thereof |
CN114344559B (en) * | 2022-02-28 | 2022-09-20 | 西安交通大学口腔医院 | Soft degradable periodontal plug treatment agent and preparation method thereof |
CN114306729B (en) * | 2022-03-15 | 2022-05-27 | 中国人民解放军总医院第一医学中心 | Biological antibacterial film-forming liquid medical dressing and preparation method thereof |
CN114712552B (en) * | 2022-03-30 | 2022-10-28 | 湖南省天香生物科技有限责任公司 | Antibacterial and anti-inflammatory liquid band-aid |
CN115197407A (en) * | 2022-08-10 | 2022-10-18 | 武汉科技大学 | Preparation and application of degradable biological copolyester and antiviral copolyester film |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763412A (en) * | 1997-04-08 | 1998-06-09 | Becton Dickinson And Company | Film-forming composition containing chlorhexidine gluconate |
US20070238807A1 (en) * | 2006-04-06 | 2007-10-11 | Safir Adam L | Water resistant film forming compositions incorporating hydrophilic activities |
US7649045B2 (en) * | 2005-01-28 | 2010-01-19 | Rohm And Haas Company | Medical films and articles prepared from emulsion polymers |
US20150150988A1 (en) * | 2010-02-02 | 2015-06-04 | Poly-Med, Inc. | In Situ Film-Forming Bioactive Solutions of Absorbable Multiblock Copolymers |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1023068C (en) * | 1988-12-15 | 1993-12-15 | 沈阳市石油化工设计研究院 | Production method of transparent medical polymer dressing |
IN172390B (en) * | 1989-07-18 | 1993-07-10 | Ethicon Inc | |
CA2183415C (en) * | 1995-09-01 | 2000-10-10 | Minh Q. Hoang | A new skin preparation composition |
AU734610B2 (en) * | 1997-01-10 | 2001-06-21 | Flowers Park Ltd | Cyanoacrylate compositions comprising an antimicrobial agent |
EP1778479A2 (en) * | 2004-07-16 | 2007-05-02 | Poly-Med, Inc. | Hemostatix microfibrous constructs |
AU2008347253B2 (en) | 2007-12-31 | 2012-04-19 | 3M Innovative Properties Company | Antimicrobial compositions |
WO2010107163A1 (en) * | 2009-03-17 | 2010-09-23 | 주식회사 바이오폴 | Liquid bandage for protecting skin and injury and manufacturing method for the same |
US20110152925A1 (en) * | 2009-12-22 | 2011-06-23 | Schorr Phillip A | Skin Preparation That Immobilizes Bacteria |
EP2557918A2 (en) * | 2010-04-14 | 2013-02-20 | Avery Dennison Corporation | Methods for increasing effectiveness of antimicrobial agents in polymeric films |
WO2011143131A1 (en) * | 2010-05-11 | 2011-11-17 | Shaosheng Dong | Film forming personal care compositions and methods |
CN102258455B (en) * | 2010-05-28 | 2014-09-17 | 上海市计划生育科学研究所 | Film coating agent containing steroid hormone and its preparation method |
CN101879283B (en) * | 2010-06-13 | 2013-01-02 | 中国人民解放军第三军医大学 | Novel membrane spraying preparation for skin trauma and preparation method |
FR2976806B1 (en) * | 2011-06-22 | 2013-06-28 | Urgo Lab | FILMOGENIC TOPICAL COMPOSITION AND USE THEREOF FOR THE TREATMENT OF MYCOSES |
RU2013155713A (en) * | 2011-07-06 | 2015-08-20 | Профибрикс Бв | COMPOSITIONS FOR TREATMENT OF THE RAS |
CN102406959B (en) | 2011-11-29 | 2013-12-25 | 江苏德达医药科技有限公司 | Liquid bandage containing povidone iodine and preparation method thereof |
US8877882B1 (en) * | 2013-10-04 | 2014-11-04 | Rochal Industries Llp | Non-self-adherent coating materials |
CN105012960A (en) * | 2014-04-16 | 2015-11-04 | 上海现代药物制剂工程研究中心有限公司 | Film-forming gel composition, application and wound protecting material |
CN104971377A (en) * | 2015-06-23 | 2015-10-14 | 潘秀娟 | Liquid wound glue and preparation method |
CN105363066B (en) * | 2015-11-30 | 2018-07-06 | 江苏华能药业有限公司 | A kind of liquid adhesive bandage |
CN105477341B (en) * | 2015-12-16 | 2020-05-22 | 成都中医药大学 | Liquid adhesive bandage and preparation method thereof |
CN105434404B (en) * | 2015-12-18 | 2018-07-17 | 江苏海智生物医药有限公司 | A kind of plastics for protecting wound surface |
-
2016
- 2016-12-30 EP EP16907675.9A patent/EP3478234A4/en active Pending
- 2016-12-30 WO PCT/US2016/069420 patent/WO2018004739A1/en unknown
- 2016-12-30 CN CN201680059582.8A patent/CN108135745B/en active Active
- 2016-12-30 US US15/395,734 patent/US11471481B2/en active Active
- 2016-12-30 JP JP2018568750A patent/JP7054212B2/en active Active
-
2018
- 2018-06-26 HK HK18108164.3A patent/HK1248511A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763412A (en) * | 1997-04-08 | 1998-06-09 | Becton Dickinson And Company | Film-forming composition containing chlorhexidine gluconate |
US7649045B2 (en) * | 2005-01-28 | 2010-01-19 | Rohm And Haas Company | Medical films and articles prepared from emulsion polymers |
US20070238807A1 (en) * | 2006-04-06 | 2007-10-11 | Safir Adam L | Water resistant film forming compositions incorporating hydrophilic activities |
US20150150988A1 (en) * | 2010-02-02 | 2015-06-04 | Poly-Med, Inc. | In Situ Film-Forming Bioactive Solutions of Absorbable Multiblock Copolymers |
Non-Patent Citations (1)
Title |
---|
See also references of EP3478234A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110639055A (en) * | 2019-11-07 | 2020-01-03 | 广州市福托康生物科技有限公司 | Wound care ointment and preparation method thereof |
CN110755673A (en) * | 2019-11-07 | 2020-02-07 | 广州市福托康生物科技有限公司 | Sodium carboxymethylcellulose liquid dressing and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
US20180000858A1 (en) | 2018-01-04 |
US11471481B2 (en) | 2022-10-18 |
JP7054212B2 (en) | 2022-04-13 |
CN108135745B (en) | 2021-05-14 |
HK1248511A1 (en) | 2018-10-19 |
EP3478234A4 (en) | 2020-02-26 |
CN108135745A (en) | 2018-06-08 |
JP2019527090A (en) | 2019-09-26 |
EP3478234A1 (en) | 2019-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11471481B2 (en) | Rapid-deposition thin-film forming compositions as effective wound care treatment | |
JP3560977B2 (en) | Gels for the treatment of skin disorders and for disinfecting their skin | |
CN1089587C (en) | Stable cross-linked compound of polyvinyl pyrrolidone and iodine and method for preparation of said compound | |
EP3106157B1 (en) | Antiseptic compositions comprising silver ions and menthol and uses thereof | |
EP2496215B1 (en) | Antimicrobial and anti-acne formulations | |
AU2023203406A1 (en) | Emollient topical disinfectants | |
TW201216859A (en) | Disinfectant and antiseptic formulation having reduced iodine content | |
JPH07109220A (en) | Ointment for medical treatment of wound | |
US6521243B2 (en) | Ionic chitosan -iodine complexes: antiseptic hydrogels and wound healing promoters | |
US20200000088A1 (en) | Topical antiseptic system | |
CN111991417A (en) | Hypochlorous acid gel with physiological responsiveness and application thereof in skin wound surface | |
WO2009054992A1 (en) | Antimicrobial compositions comprising docusate | |
US6923990B2 (en) | Stabilized silver-ion amine complex compositions and methods | |
JP3054758B2 (en) | Trauma composition | |
CA3135535A1 (en) | Liquid composition for influencing the microbiota on a subject's skin comprising chitosan | |
RU2427379C1 (en) | Diabetic foot prevention and care composition | |
TWI835711B (en) | Emollient topical disinfectants | |
CN116568272A (en) | Soluble polyelectrolyte complexes of polymeric biguanide microbiocides and glycosaminoglycans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16907675 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018568750 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016907675 Country of ref document: EP Effective date: 20190129 |